- Home
- WEA vs KRRO Comparison
WEA vs KRRO Comparison
Compare WEA & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- KRRO
- Stock Information
- Founded
- WEA 2002
- KRRO 2014
- Country
- WEA United States
- KRRO United States
- Employees
- WEA N/A
- KRRO N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- WEA Finance
- KRRO Health Care
- Exchange
- WEA Nasdaq
- KRRO Nasdaq
- Market Cap
- WEA 129.6M
- KRRO 147.4M
- IPO Year
- WEA N/A
- KRRO 2019
- Fundamental
- Price
- WEA $10.91
- KRRO $20.26
- Analyst Decision
- WEA
- KRRO Strong Buy
- Analyst Count
- WEA 0
- KRRO 8
- Target Price
- WEA N/A
- KRRO $96.71
- AVG Volume (30 Days)
- WEA 46.1K
- KRRO 145.7K
- Earning Date
- WEA 01-01-0001
- KRRO 08-12-2025
- Dividend Yield
- WEA 7.87%
- KRRO N/A
- EPS Growth
- WEA N/A
- KRRO N/A
- EPS
- WEA N/A
- KRRO N/A
- Revenue
- WEA N/A
- KRRO $6,281,000.00
- Revenue This Year
- WEA N/A
- KRRO $65.08
- Revenue Next Year
- WEA N/A
- KRRO N/A
- P/E Ratio
- WEA N/A
- KRRO N/A
- Revenue Growth
- WEA N/A
- KRRO N/A
- 52 Week Low
- WEA $9.60
- KRRO $10.29
- 52 Week High
- WEA $11.29
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- WEA 56.73
- KRRO 70.12
- Support Level
- WEA $10.82
- KRRO $14.15
- Resistance Level
- WEA $10.95
- KRRO $16.89
- Average True Range (ATR)
- WEA 0.07
- KRRO 1.67
- MACD
- WEA 0.01
- KRRO 0.46
- Stochastic Oscillator
- WEA 78.95
- KRRO 93.51
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.